Related Experiment Video
Updated: Aug 19, 2025
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Targeting NaPi2b in ovarian cancer
Susana Banerjee1, Ronny Drapkin2, Debra L Richardson3
1Royal Marsden NHS Foundation Trust, London, United Kingdom.
Abstract:
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment options are limited, particularly in the platinum-resistant setting. NaPi2b is a cell surface sodium-dependent phosphate transporter that regulates phosphate homeostasis under normal physiological conditions and is a lineage marker that is expressed in select cancers, including ovarian, lung, thyroid, and breast cancers, with limited expression in normal tissues. Based on its increased expression in ovarian tumors, NaPi2b is a promising candidate to be studied as a biomarker for treatment and patient selection in ovarian cancer. In preclinical studies, the use of antibodies against NaPi2b showed that this protein can be exploited for tumor mapping and therapeutic targeting. Emerging data from phase 1 and 2 clinical trials in ovarian cancer have suggested that NaPi2b can be successfully detected in patient biopsy samples using immunohistochemistry, and the NaPi2b-targeting antibody-drug conjugate under evaluation appeared to elicit therapeutic responses. The aim of this review is to examine literature supporting NaPi2b as a novel biomarker for potential treatment and patient selection in ovarian cancer and to discuss the critical next steps and future analyses necessary to drive the study of this biomarker and therapeutic targeting forward.
Insights
Novel biomarkers like NaPi2b are crucial for ovarian cancer treatment. This sodium-dependent phosphate transporter shows promise for targeted therapies and patient selection, especially in platinum-resistant cases.
Area of Science:
- Oncology
- Biomarker Discovery
- Molecular Imaging
Background:
- Ovarian cancer treatment relies heavily on platinum-based chemotherapy, with limited options for platinum-resistant disease.
- Novel biomarkers are essential for developing targeted therapies and improving patient selection in ovarian cancer.
- NaPi2b, a sodium-dependent phosphate transporter, is upregulated in ovarian tumors with limited expression in normal tissues.
Purpose of the Study:
- To review the literature supporting NaPi2b as a biomarker for ovarian cancer treatment and patient selection.
- To discuss the potential of NaPi2b for therapeutic targeting in ovarian cancer.
- To outline future research directions for NaPi2b biomarker and therapeutic development.
Main Methods:
- Literature review of preclinical and clinical studies on NaPi2b in ovarian cancer.
- Analysis of NaPi2b expression in ovarian tumors and normal tissues.
- Evaluation of NaPi2b-targeting antibodies and antibody-drug conjugates in preclinical and clinical settings.
Main Results:
- NaPi2b is expressed in select cancers, including ovarian cancer, making it a promising biomarker.
- Preclinical studies demonstrate NaPi2b's utility for tumor mapping and therapeutic targeting.
- Phase 1 and 2 clinical trials indicate successful detection of NaPi2b in patient biopsies and therapeutic responses to NaPi2b-targeting agents.
Conclusions:
- NaPi2b is a viable biomarker candidate for ovarian cancer treatment and patient selection.
- Targeting NaPi2b with antibody-drug conjugates shows therapeutic potential in ovarian cancer.
- Further research and clinical validation are necessary to advance NaPi2b-based strategies for ovarian cancer.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
